IN2014DN03424A - - Google Patents

Info

Publication number
IN2014DN03424A
IN2014DN03424A IN3424DEN2014A IN2014DN03424A IN 2014DN03424 A IN2014DN03424 A IN 2014DN03424A IN 3424DEN2014 A IN3424DEN2014 A IN 3424DEN2014A IN 2014DN03424 A IN2014DN03424 A IN 2014DN03424A
Authority
IN
India
Prior art keywords
receptor
fprl
modulators
pharmaceuticals
preparing
Prior art date
Application number
Inventor
Richard L Beard
Tien T Duong
John E Donello
Veena Viswanath
Michael E Garst
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47116500&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014DN03424(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014DN03424A publication Critical patent/IN2014DN03424A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/30—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by halogen atoms, or by nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/38—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atom of at least one amino group being part of any of the groups, X being a hetero atom, Y being any atom, e.g. N-acylaminosulfones
    • C07C317/42—Y being a hetero atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
    • C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C317/50—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/23—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C323/39—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton at least one of the nitrogen atoms being part of any of the groups, X being a hetero atom, Y being any atom
    • C07C323/43—Y being a hetero atom
    • C07C323/44—X or Y being nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/57—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C323/58—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton
    • C07C323/59—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups with amino groups bound to the carbon skeleton with acylated amino groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C07K5/06113—Asp- or Asn-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06147—Dipeptides with the first amino acid being heterocyclic and His-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06156—Dipeptides with the first amino acid being heterocyclic and Trp-amino acid; Derivatives thereof
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)

Abstract

The present invention relates to novel amide derivatives of N urea substituted amino acids processes for preparing them pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of the N formyl peptide receptor like 1 (FPRL 1) receptor.
IN3424DEN2014 2011-10-26 2012-10-23 IN2014DN03424A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161551772P 2011-10-26 2011-10-26
PCT/US2012/061448 WO2013062947A1 (en) 2011-10-26 2012-10-23 Amide derivatives of n-urea substituted amino acids as formyl peptide receptor like-1 (fprl-1) receptor modulators

Publications (1)

Publication Number Publication Date
IN2014DN03424A true IN2014DN03424A (en) 2015-06-05

Family

ID=47116500

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3424DEN2014 IN2014DN03424A (en) 2011-10-26 2012-10-23

Country Status (32)

Country Link
US (9) US8658803B2 (en)
EP (2) EP3078656B1 (en)
JP (3) JP5982001B2 (en)
KR (1) KR102051687B1 (en)
CN (2) CN106518742B (en)
AR (2) AR088535A1 (en)
AU (3) AU2012329098B2 (en)
BR (2) BR122019025505B1 (en)
CA (1) CA2853648C (en)
CL (1) CL2014001080A1 (en)
CO (1) CO6960509A2 (en)
CY (1) CY1121604T1 (en)
DK (1) DK2770989T3 (en)
ES (2) ES2708997T3 (en)
HR (1) HRP20181934T1 (en)
HU (1) HUE040145T2 (en)
IL (3) IL232204B (en)
IN (1) IN2014DN03424A (en)
LT (1) LT2770989T (en)
MX (2) MX376348B (en)
MY (1) MY172013A (en)
PH (2) PH12014500928B1 (en)
PL (1) PL2770989T3 (en)
PT (1) PT2770989T (en)
RS (1) RS58111B1 (en)
RU (2) RU2629205C2 (en)
SG (2) SG11201401818RA (en)
SI (1) SI2770989T1 (en)
TW (1) TWI631099B (en)
UA (1) UA115043C2 (en)
WO (1) WO2013062947A1 (en)
ZA (1) ZA201403222B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10206813B2 (en) 2009-05-18 2019-02-19 Dose Medical Corporation Implants with controlled drug delivery features and methods of using same
US12478503B2 (en) 2009-05-18 2025-11-25 Glaukos Corporation Implants with controlled drug delivery features and methods of using same
CN106518742B (en) 2011-10-26 2020-01-21 阿勒根公司 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor-like-1 (FPRL-1) receptor modulators
US8541577B2 (en) * 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
BR112015021371B1 (en) 2013-03-06 2021-04-13 Allergan, Inc USE OF FORMIL PEPTIDE 2 RECEPTOR AGONISTS TO TREAT EYE INFLAMMATORY DISEASES
BR112015021392B1 (en) * 2013-03-06 2021-11-16 Allergan, Inc USE OF FORMIL 2 PEPTIDE RECEPTOR AGONISTS TO TREAT DERMATOLOGICAL DISEASES
JP6653253B2 (en) * 2013-07-16 2020-02-26 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
AR097279A1 (en) 2013-08-09 2016-03-02 Actelion Pharmaceuticals Ltd DERIVATIVES OF BENZIMIDAZOLIL-METIL UREA AS ALX RECEIVER AGONISTS
TWI537251B (en) 2013-10-09 2016-06-11 長庚大學 Fpr1 antagonist derivatives and use thereof
WO2015077451A1 (en) * 2013-11-21 2015-05-28 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
BR112016011755B1 (en) 2013-11-28 2023-05-02 Kyorin Pharmaceutical Co., Ltd UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT, ITS USE AND PHARMACEUTICAL COMPOSITION INCLUDING THEM
US9663457B2 (en) 2014-04-09 2017-05-30 Allergan, Inc. Carbamoyl hydrazine derivatives as formyl peptide modulators
AU2015264021B2 (en) * 2014-05-21 2020-02-27 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators
WO2016189877A1 (en) 2015-05-27 2016-12-01 Kyorin Pharmaceutical Co., Ltd. Urea derivative or pharmacologically acceptable salt thereof
BR112017024966A2 (en) 2015-05-27 2018-08-07 Kyorin Seiyaku Kk derived from urea or pharmacologically acceptable salt of the same
WO2017023907A1 (en) * 2015-08-05 2017-02-09 Allergan, Inc. Phenyl urea analogs as formyl peptide repceptor 1 (fpr1) selective agonists
EP3436431A1 (en) 2016-03-28 2019-02-06 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
CA3020316A1 (en) * 2016-04-12 2017-10-19 Allergan, Inc. Phenyl urea derivatives as n-formyl peptide receptor modulators
TWI746660B (en) * 2016-10-06 2021-11-21 日商第一三共股份有限公司 Urea derivatives and use thereof
JP2020015664A (en) * 2016-11-21 2020-01-30 宇部興産株式会社 Nitrogen-containing polycyclic heterocyclic derivative
US10608869B2 (en) * 2017-03-20 2020-03-31 Nicira, Inc. Handling control-plane connectivity loss in virtualized computing environments
KR102803660B1 (en) 2018-03-05 2025-05-02 브리스톨-마이어스 스큅 컴퍼니 Phenylpyrrolidinone formyl peptide 2 receptor agonist
EP4234014A1 (en) * 2022-02-28 2023-08-30 Insusense ApS Amino acid based carbamates and/or ureas for the treatment of sortilin dependent diseases
WO2025144935A1 (en) * 2023-12-26 2025-07-03 Development Center For Biotechnology Heterocycle compounds as formyl peptide receptor modulators
WO2025233915A1 (en) 2024-05-10 2025-11-13 Allgenesis Biotherapeutics Inc. Use of an agonist of formyl peptide receptors 1 and 2 for treating ocular inflammatory diseases

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2533210A1 (en) 1982-09-17 1984-03-23 Lyon I Universite Claude SWEETENERS OF SYNTHESIS
US4521210A (en) 1982-12-27 1985-06-04 Wong Vernon G Eye implant for relieving glaucoma, and device and method for use therewith
US5284828A (en) 1990-05-14 1994-02-08 Fujisawa Pharmaceutical Co. Ltd. Peptide compound and its preparation
JP3387948B2 (en) 1992-12-04 2003-03-17 富山化学工業株式会社 Novel phenylalanine derivative or salt thereof
AU667995B2 (en) * 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
FI961819L (en) * 1993-11-05 1996-04-29 Warner Lambert Co Protein:Substituted di- and tripeptide inhibitors of farnesyltransferase
JPH11171896A (en) * 1995-09-19 1999-06-29 Kirin Brewery Co Ltd New peptide compound and its pharmaceutical composition
US6423689B1 (en) * 1997-12-22 2002-07-23 Warner-Lambert Company Peptidyl calcium channel blockers
US6548637B1 (en) * 1998-06-18 2003-04-15 Sepracor, Inc. Ligands for opioid receptors
US6243689B1 (en) 1998-12-29 2001-06-05 Robert G. Norton System and method for authorizing electronic funds transfer at a point of sale
WO2001014328A2 (en) 1999-08-20 2001-03-01 Merck & Co., Inc. Substituted ureas as cell adhesion inhibitors
EP1162194A1 (en) 2000-06-06 2001-12-12 Aventis Pharma Deutschland GmbH Factor VIIa inhibitory (thio)urea derivatives, their preparation and their use
DE10063008A1 (en) 2000-12-16 2002-06-20 Merck Patent Gmbh carboxamide
WO2002068586A2 (en) * 2001-01-19 2002-09-06 The Scripps Research Institute Hiv/fiv protease inhibitors
ES2275937T3 (en) * 2001-12-12 2007-06-16 Wilex Ag SELECTIVE ARILGUANIDINE PEPTIDES AS UROCINASE INHIBITORS.
MXPA05002493A (en) 2002-09-05 2005-05-27 Neurosearch As Diarylurea derivatives and their use as chloride channel blockers.
AU2003259007A1 (en) * 2002-10-31 2004-05-25 Amersham Biosciences Ab Use of urea variants as affinity ligands
ATE447586T1 (en) 2002-11-07 2009-11-15 Takeda Pharmaceutical FPRL1 LIGANDS AND THEIR USE
KR100527361B1 (en) * 2003-04-01 2005-11-09 주식회사 프로메디텍 A deformylase inhibitor, a process for the preparation thereof, and a composition comprising the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CN1894580A (en) * 2003-11-07 2007-01-10 阿卡蒂亚药品公司 The lipoxin receptor, FPRL1, as a tool for identifying compounds effective in the treatment of pain and inflammation
EP1692502A2 (en) * 2003-11-07 2006-08-23 Acadia Pharmaceuticals Inc. Use of the lipoxin receptor, fprl1, as a tool for identifying compounds effective in the treatment of pain and inflammation
JP4769082B2 (en) 2003-12-17 2011-09-07 武田薬品工業株式会社 Urea derivatives, their production and use
GB0417802D0 (en) * 2004-08-10 2004-09-15 Novartis Ag Organic compounds
AU2005302608A1 (en) 2004-10-28 2006-05-11 Merck & Co., Inc. Pyrimidine and quinoline potentiators of metabotropic glutamate receptors
WO2006063113A2 (en) 2004-12-07 2006-06-15 Portola Pharmaceuticals, Inc. Ureas as factor xa inhibitors
WO2006065755A2 (en) 2004-12-13 2006-06-22 Glaxo Group Limited Quaternary ammonium salts of fused hetearomatic amines as novel muscarinic acetylcholine receptor antagonists
WO2007076055A2 (en) 2005-12-22 2007-07-05 Entremed, Inc. Compositions and methods comprising proteinase activated receptor antagonists
US7884180B2 (en) 2006-09-18 2011-02-08 Compugen Ltd Peptides which bind to G protein-coupled receptors
AR065093A1 (en) 2007-02-05 2009-05-13 Merck Frosst Canada Ltd PHARMACEUTICAL COMPOUNDS INHIBITING THE BIOSYNTHESIS OF LEUCOTRIENS
KR20090121832A (en) 2008-05-23 2009-11-26 인제대학교 산학협력단 2- (2-hydroxybenzoyl) hydrazinecarboxyamide derivative or pharmaceutically acceptable salt thereof, preparation method thereof, and pharmaceutical composition for selective immunosuppression containing the same as an active ingredient
US20100035932A1 (en) 2008-08-07 2010-02-11 Schepetkin Igor A Novel formyl peptide receptor like 1 agonists that induce macrophage tumor necrosis factor alpha and computational structure-activity relationship analysis of thereof
TW201035111A (en) * 2008-12-23 2010-10-01 Biosource Pharm Inc Antibiotic compositions for the treatment of gram negative infections
EP2585054A1 (en) 2010-06-24 2013-05-01 Allergan, Inc. Derivatives of cycloalkyl- and cycloalkenyl-1,2-dicarboxylic acid compounds having formyl peptide receptor like-1 (fprl-1) agonist or antagonist activity
AU2011336973A1 (en) 2010-12-03 2013-07-11 Allergan, Inc. Pharmaceutical compositions comprising 3,4- dihydroisoquinolin-2(1 H)-yl-3-phenylurea derivatives having formyl peptide receptor like-1 (FPRL-1) agonist or antagonist activity
US8580817B2 (en) 2011-02-11 2013-11-12 Allergan, Inc. 1-(1-OXO-1,2,3,4-tetrahydroisoquinolin-7-YL)urea derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
US8653299B2 (en) 2011-03-17 2014-02-18 Allergan, Inc. Dihydronaphthalene and naphthalene derivatives as N-formyl peptide receptor like-1 (FPRL-1) receptor modulators
AU2012271562A1 (en) 2011-06-17 2014-01-30 Allergan, Inc. D -serine for the treatment of visual system disorders
GB2494851A (en) * 2011-07-07 2013-03-27 Kalvista Pharmaceuticals Ltd Plasma kallikrein inhibitors
AU2012282977A1 (en) 2011-07-11 2014-02-06 Allergan, Inc. Polycyclic pyrrolidine-2,5-dione derivatives as -formyl peptide receptor like-1 (FPRLl-1) receptor modulators
CN106518742B (en) * 2011-10-26 2020-01-21 阿勒根公司 Amide derivatives of N-urea substituted amino acids as formyl peptide receptor-like-1 (FPRL-1) receptor modulators
US8541577B2 (en) 2011-11-10 2013-09-24 Allergan, Inc. Aryl urea derivatives as N-formyl peptide receptors like-1 (FPRL-1) receptor modulators
US8492556B2 (en) 2011-11-10 2013-07-23 Allergan, Inc. 2,5-Dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor like-1 (FPRL-1) receptor modulators
EP2814815A1 (en) 2012-02-16 2014-12-24 Allergan, Inc. Imidazolidine-2,4-dione derivatives as n-formyl peptide receptor 2 modulators
JP2015520130A (en) 2012-04-16 2015-07-16 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ (2-Ureidoacetamido) alkyl derivatives as modulators of formyl peptide receptor 2
BR112015021392B1 (en) * 2013-03-06 2021-11-16 Allergan, Inc USE OF FORMIL 2 PEPTIDE RECEPTOR AGONISTS TO TREAT DERMATOLOGICAL DISEASES
BR112015021371B1 (en) 2013-03-06 2021-04-13 Allergan, Inc USE OF FORMIL PEPTIDE 2 RECEPTOR AGONISTS TO TREAT EYE INFLAMMATORY DISEASES
JP6653253B2 (en) 2013-07-16 2020-02-26 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ Derivatives of N-urea substituted amino acids as formyl peptide receptor modulators
WO2015042071A1 (en) 2013-09-19 2015-03-26 Allergan, Inc. Diphenyl urea derivatives as formyl peptide receptor modulators
WO2015059998A1 (en) 2013-10-24 2015-04-30 トヨタ自動車株式会社 Positive electrode active material for sodium batteries, and sodium battery
WO2015077451A1 (en) 2013-11-21 2015-05-28 Allergan, Inc. Phenylcarbamate derivatives as formyl peptide receptor modulators
AU2015264021B2 (en) 2014-05-21 2020-02-27 Allergan, Inc. Imidazole derivatives as formyl peptide receptor modulators

Also Published As

Publication number Publication date
US8993780B2 (en) 2015-03-31
MX376348B (en) 2025-03-07
KR102051687B1 (en) 2019-12-17
JP5982001B2 (en) 2016-08-31
TWI631099B (en) 2018-08-01
EP3078656A1 (en) 2016-10-12
EP2770989B1 (en) 2018-09-05
RU2017129434A (en) 2019-02-04
KR20140111646A (en) 2014-09-19
IL267659A (en) 2019-08-29
BR112014010042A8 (en) 2017-06-20
BR122019025505B1 (en) 2022-02-22
HRP20181934T1 (en) 2019-01-25
US20240285584A1 (en) 2024-08-29
WO2013062947A1 (en) 2013-05-02
CO6960509A2 (en) 2014-05-30
EP2770989A1 (en) 2014-09-03
JP6804580B2 (en) 2020-12-23
MX357737B (en) 2018-07-23
TW201331168A (en) 2013-08-01
ES2708997T3 (en) 2019-04-12
BR112014010042B1 (en) 2022-03-03
US20130109866A1 (en) 2013-05-02
RU2017129434A3 (en) 2020-10-09
IL267659B (en) 2021-10-31
UA115043C2 (en) 2017-09-11
PH12019500171B1 (en) 2022-08-12
CA2853648C (en) 2023-01-24
PL2770989T3 (en) 2019-01-31
SG11201401818RA (en) 2014-05-29
US20180228772A1 (en) 2018-08-16
US8658803B2 (en) 2014-02-25
US20140094614A1 (en) 2014-04-03
CA2853648A1 (en) 2013-05-02
JP2016216497A (en) 2016-12-22
SG10201903266YA (en) 2019-05-30
EP3078656B1 (en) 2020-07-01
US10993931B2 (en) 2021-05-04
RU2744577C2 (en) 2021-03-11
US9351948B2 (en) 2016-05-31
US20170119737A1 (en) 2017-05-04
MX2014005047A (en) 2015-09-04
US20190343804A1 (en) 2019-11-14
US10172832B2 (en) 2019-01-08
IL256555A (en) 2018-02-28
ES2820714T3 (en) 2021-04-22
HUE040145T2 (en) 2019-02-28
PH12019500171A1 (en) 2020-06-15
CY1121604T1 (en) 2020-05-29
RU2014120013A (en) 2015-12-10
AU2017251683A1 (en) 2017-11-09
IL256555B (en) 2020-07-30
CN104114164B (en) 2016-11-16
US9579307B2 (en) 2017-02-28
RU2629205C2 (en) 2017-08-25
AR119698A2 (en) 2022-01-05
US20160235711A1 (en) 2016-08-18
CL2014001080A1 (en) 2014-11-14
MY172013A (en) 2019-11-12
AR088535A1 (en) 2014-06-18
IL232204B (en) 2018-12-31
AU2017251683C1 (en) 2019-11-14
HK1199622A1 (en) 2015-07-10
US20150148395A1 (en) 2015-05-28
JP2014534216A (en) 2014-12-18
AU2019264555B2 (en) 2020-12-17
PT2770989T (en) 2018-12-04
BR112014010042A2 (en) 2017-06-13
JP2019089849A (en) 2019-06-13
AU2019264555A1 (en) 2019-12-05
LT2770989T (en) 2018-12-10
US9974772B2 (en) 2018-05-22
AU2017251683B2 (en) 2019-08-15
CN106518742B (en) 2020-01-21
ZA201403222B (en) 2015-07-29
AU2012329098B2 (en) 2017-08-03
PH12014500928B1 (en) 2021-03-26
CN106518742A (en) 2017-03-22
DK2770989T3 (en) 2018-12-17
PH12014500928A1 (en) 2014-06-23
RS58111B1 (en) 2019-02-28
US20220202777A1 (en) 2022-06-30
IL232204A0 (en) 2014-06-30
AU2012329098A1 (en) 2014-05-22
SI2770989T1 (en) 2018-12-31
NZ624635A (en) 2017-01-27
JP6496689B2 (en) 2019-04-03
CN104114164A (en) 2014-10-22

Similar Documents

Publication Publication Date Title
IN2014DN03424A (en)
TR201909663T4 (en) 2,5-dioxoimidazolidin-1-yl-3-phenylurea derivatives as formyl peptide receptor-like-1 (fprl-1) receptor modulators.
IN2012DN05125A (en)
MY172395A (en) Lysin glutamic acid dipeptide derivatives
MY171146A (en) Compositions of glp-1 peptides and preparation thereof
MX2015003653A (en) Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators.
MX2013013913A (en) Polypeptides.
WO2009087082A3 (en) Novel insulin derivatives having an extremely delayed time-action profile
AU2018256493A1 (en) Peptide Compositions
IN2012DN02793A (en)
PH12015502632A1 (en) Cxcr7 receptor modulators
MX364610B (en) 1-[m-carboxamido(hetero)aryl-methyl]-heterocyclyl-carboxamide derivatives.
WO2012071212A3 (en) Novel phosphonic acids as s1p receptor modulators
MX2014004210A (en) 2-oxo-piperidinyl derivatives.
WO2012158861A3 (en) Processes for the preparation of 5-azaspiro[2.4]heptane-6-carboxylic acid and its derivatives
SG195302A1 (en) Shk-based pharmaceutical compositions and methods of manufacturing and using the same
MX336578B (en) N-(IMIDAZOLIDIN-2-YLIDENE)-HETEROCYCLOPENTA[b]PYRIDINE DERIVATIVES AS MODULATORS OF ALPHA 2 ADRENERGIC RECEPTORS.
HK1259248A1 (en) Novel 1,2-bis-sulfonamide derivatives as chemokine receptor modulators
HK1198762A1 (en) N-(imidazolidin-2-ylidene)quinoline derivatives as modulators of alpha 2 adrenergic receptors
HK1199639A1 (en) Aryl urea derivatives as n-formyl peptide receptor like-1 (fprl-1) receptor modulators
MY155338A (en) Novel insulin derivatives having an extremely delayed time-action profile
HK1189891A1 (en) Sulfur derivatives as chemokine receptor modulators